PUBLICATION
A novel small molecule, AS1, reverses the negative hedonic valence of noxious stimuli
- Authors
- Esancy, K., Conceicao, L.L., Curtright, A., Tran, T., Condon, L., Lecamp, B., Dhaka, A.
- ID
- ZDB-PUB-230405-46
- Date
- 2023
- Source
- BMC Biology 21: 6969 (Journal)
- Registered Authors
- Keywords
- Analgesic, Aversion, Dopamine, Drug discovery, Pain, Reward circuitry, Valence, Zebrafish
- MeSH Terms
-
- Dopamine/metabolism
- Dopaminergic Neurons/physiology
- Chronic Pain*
- Analgesics/pharmacology
- Zebrafish/metabolism
- Animals
- PubMed
- 37013580 Full text @ BMC Biol.
Citation
Esancy, K., Conceicao, L.L., Curtright, A., Tran, T., Condon, L., Lecamp, B., Dhaka, A. (2023) A novel small molecule, AS1, reverses the negative hedonic valence of noxious stimuli. BMC Biology. 21:6969.
Abstract
Background Pain is the primary reason people seek medical care, with chronic pain affecting ~ 20% of people in the USA. However, many existing analgesics are ineffective in treating chronic pain, while others (e.g., opioids) have undesirable side effects. Here, we describe the screening of a small molecule library using a thermal place aversion assay in larval zebrafish to identify compounds that alter aversion to noxious thermal stimuli and could thus serve as potential analgesics.
Results From our behavioral screen, we discovered a small molecule, Analgesic Screen 1 (AS1), which surprisingly elicited attraction to noxious painful heat. When we further explored the effects of this compound using other behavioral place preference assays, we found that AS1 was similarly able to reverse the negative hedonic valence of other painful (chemical) and non-painful (dark) aversive stimuli without being inherently rewarding. Interestingly, targeting molecular pathways canonically associated with analgesia did not replicate the effects of AS1. A neuronal imaging assay revealed that clusters of dopaminergic neurons, as well as forebrain regions located in the teleost equivalent of the basal ganglia, were highly upregulated in the specific context of AS1 and aversive heat. Through a combination of behavioral assays and pharmacological manipulation of dopamine circuitry, we determined that AS1 acts via D1 dopamine receptor pathways to elicit this attraction to noxious stimuli.
Conclusions Together, our results suggest that AS1 relieves an aversion-imposed "brake" on dopamine release, and that this unique mechanism may provide valuable insight into the development of new valence-targeting analgesic drugs, as well as medications for other valence-related neurological conditions, such as anxiety and post-traumatic stress disorder (PTSD).
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping